Safety and Immunogenicity of the rVSV ΔG-ZEBOV-GP Ebola Virus Vaccine Candidate in Children Years and in Their Adults and/or Children Relatives Living in Lambaréné, Gabon
Condition:   Ebola Virus Disease Intervention:   Biological: rVSVΔG-ZEBOV-GP, V920 Sponsors:   Centre de Recherche Médicale de Lambaréné;   Merck Sharp & Dohme Corp. Recruiting (Source:
Source: - November 23, 2021 Category: Research Source Type: clinical trials

International Study on COVID-19 Vaccine to Assess Immunogenicity, Reactogenicity and Efficacy (InVITE)
Condition:   COVID-19 Intervention:   Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo;   Partnership for Clinical Research in Guinea/Partenariat de Recherche Clinique en Guinée (PREGUI);   National Institute of Health Resea rch and Development, Ministry of Health Republic of Indonesia;   Partnership for Research on Ebola Virus in Liberia (PREVAIL);   University Clinical Research Center, Mali;   National Institute of Medical Sciences and Nutrition, Salvador Zubiran Recruiting (Source:
Source: - October 27, 2021 Category: Research Source Type: clinical trials